ImmunityBio, Inc.
IBRX
$8.71
$0.506.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.27M | 31.78M | 26.42M | 16.51M | 7.21M |
| Total Other Revenue | 13.00K | 281.00K | 4.00K | 8.00K | 346.00K |
| Total Revenue | 38.29M | 32.06M | 26.43M | 16.52M | 7.55M |
| Cost of Revenue | 382.00K | 177.00K | 136.00K | 58.00K | -- |
| Gross Profit | 37.90M | 31.88M | 26.29M | 16.46M | 7.55M |
| SG&A Expenses | 35.33M | 37.38M | 43.44M | 33.65M | 38.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 102.97M | 87.69M | 97.71M | 80.95M | 76.95M |
| Operating Income | -64.68M | -55.63M | -71.29M | -64.43M | -69.40M |
| Income Before Tax | -62.09M | -67.31M | -92.31M | -129.90M | -59.18M |
| Income Tax Expenses | -135.00K | -35.00K | 269.00K | -234.00K | -- |
| Earnings from Continuing Operations | -61.96M | -67.27M | -92.57M | -129.67M | -59.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 14.00K | 21.00K | 19.00K | 20.00K | 17.00K |
| Net Income | -61.94M | -67.25M | -92.56M | -129.65M | -59.16M |
| EBIT | -64.68M | -55.63M | -71.29M | -64.43M | -69.40M |
| EBITDA | -60.92M | -51.68M | -67.41M | -60.60M | -65.26M |
| EPS Basic | -0.06 | -0.07 | -0.10 | -0.15 | -0.08 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.06 | -0.10 | -0.05 |
| EPS Diluted | -0.06 | -0.07 | -0.10 | -0.15 | -0.09 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.06 | -0.10 | -0.05 |
| Average Basic Shares Outstanding | 989.68M | 946.60M | 888.22M | 853.16M | 733.20M |
| Average Diluted Shares Outstanding | 989.68M | 946.60M | 888.22M | 853.16M | 734.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |